[2 cases report of open heart surgery with non-blood transfusion in severe valvular heart disease with cardiac cachexia--the efficacy of recombinant human erythropoietin].
Open heart surgery with non-blood transfusion was performed in 2 cases of severe mitral valve disease with cardiac cachexia by administering recombinant human erythropoietin (EPO). Case 1 was a 72-year-old and case 2 was a 66-year-old woman whose % usual body weight was 71-79% and Ht value on admission was 28.5-30%. Both patients were administered 9000-18000 U/week of EPO and ferrous sulfate pre- and postoperatively. In each case 800-1200 ml of autologous blood was drawn within 3 weeks preoperatively without hemodynamic change or decrease of Ht value. Both patients were received mitral valve replacement with non-blood transfusion. Preoperative administration of EPO and autologous blood preservation allowed open heart surgery with non-blood transfusion even in such a serious case as cardiac cachexia.
Masai
T
T
Department of Cardiovascular Surgery, Osaka Police Hospital, Japan.
Sakakibara
T
T
Watanabe
S
S
Akedo
H
H
Furutani
Y
Y
Kodama
K
K
D000368:Aged; D001804:Blood Transfusion, Autologous; D002100:Cachexia / Q000150:complications*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006350:Heart Valve Prosthesis; D006400:Hematocrit; D006801:Humans; D008943:Mitral Valve / Q000601:surgery; D008944:Mitral Valve Insufficiency / Q000150:complications / Q000601:surgery*; D008946:Mitral Valve Stenosis / Q000150:complications / Q000601:surgery*; D011300:Preoperative Care; D011994:Recombinant Proteins / Q000627:therapeutic use; D014262:Tricuspid Valve Insufficiency / Q000150:complications / Q000601:surgery*
D011994:Recombinant Proteins; D004921:Erythropoietin